ClinicalTrials.gg
RecruitingNCT07765888Updated Nov 12, 2026

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

A Phase 3 interventional study of Tilrekimig and Placebo in Atopic Dermatitis, sponsored by Pfizer. Recruiting at 23 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 12, 2026First sites in Japan and CanadaSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Planned enrollment
14th of 47
375 · median 121
Started
2026
with 3 others
Phase 3
17 of 58
4 open now
Primary completion
2028-03
later than 8 of 12 live
Registered
55th of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 8 of the 12 other live ones, and was the 55th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated.

  • This study is seeking participants who: Are aged 12 years or older.
  • Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
  • Are not having an effective treatment result from medicines that are applied on skin for AD.
  • Are considered by their doctors to have moderate to severe AD.

Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20.

Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic dermatitis
  • Immune system diseases
  • skin diseases, genetic
  • Dermatitis
  • Skin Diseases, Eczematous
  • skin diseases
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 12 years of age or older
  • Must meet the following AD criteria:

    1. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1
    2. An inadequate response to standard of care treatments {eg, at least medium potency topical (TCS)} consistent with AD treatment guidelines
    3. Moderate-to-severe eczema for at least 1 year
  • Adolescent participants must be up to date on immunizations per local guidance.

Exclusion criteria

Exclusion Criteria:

  • Disease
  • Significant Infection History or Active Infection
  • Known or Suspected Immunodeficiency/
  • Significant psychiatric illness or suicidality
  • Clinically significant hepatic, renal, or hematologic abnormalities
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Tilrekimig

    Subcutaneous injections given over 20 weeks

    Drug: Tilrekimig

  • Placebo comparator
    Placebo

    Subcutaneous injections given over 20 weeks

    Drug: Placebo

Interventions

  • Subcutaneous Injections at required timepoints

    Also known as: PF-07275315

  • DrugPlacebo

    Subcutaneous Injections at required timepoints

06

What researchers measure

Primary outcomes

  1. Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placebo

    Time frame: Week 16

  2. Difference in the proportion of Validated Investigator Global Assessment (vIGA)-AD™ 0/1 responders between tilrekimig versus placebo

    Time frame: Week 16

Secondary outcomes

  1. Difference in the proportion of revised investigator's global assessment (rIGA) 0/1 responders between tilrekimig versus placebo

    Time frame: Week 16

  2. Difference in the proportion of Eczema and Severity Index (EASI)90 responders between tilrekimig versus placebo

    Time frame: Week 16

  3. Difference in the proportion of Dermatology Life Quality Index (DLQI) responders between tilrekimig versus placebo

    For participants \>= 16 yrs of age

    Time frame: Week 16

  4. Difference in the proportion of Peak Pruritus Numerical Rating Scale (PP-NRS)4 responders between tilrekimig versus placebo

    Time frame: Weeks 2, 4, 6, 8, and 16

  5. Difference in the mean percent change from baseline (CFB) in EASI total score, between tilrekimig versus placebo

    Time frame: Week 16

  6. Incidence of treatment emergent Adverse Events (AE)s, Serious Adverse Events (SAE)s and AEs leading to discontinuation

    Time frame: For each participant from the time the participant provides informed consent, through and including a minimum of 16 weeks after the last administration of the study intervention.

  7. Incidence of clinically significant changes in vital signs, and laboratory tests

    Time frame: For each participant from the time the participant provides informed consent, through and including a minimum of 16 weeks after the last administration of the study intervention

  8. Difference in the proportion of EASI75 responders

    Time frame: Weeks 2, 4, 8, 12, 20, 24 and 36

  9. Difference in the proportion of vIGA-AD™ 0/1 response

    Time frame: Weeks 2, 4, 8, 12, 20, 24 and 36

  10. Difference in the proportion of rIGA 0/1 response

    Time frame: Weeks 2, 4, 8, 12, 20, 24 and 36

  11. Difference in the proportion of vIGA-AD™ 0 response defined as achieving a vIGA-AD(™) score of clear (0) (on a 5-point scale)

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24 and 36

  12. Difference in the proportion of PP-NRS4 response at every week except those included as key secondary endpoints

    Time frame: Week 1 through Week 24 (except Weeks 2, 4, 6, 8, and 16), plus Week 36

  13. Difference in the proportion of EASI50, EASI90 and EASI100 (≥50%, ≥90% and 100% improvement from baseline in EASI)

    Time frame: Time frame for both EASI50 and EASI100 is Weeks 2, 4, 8, 12, 16, 20, 24, and 36. Time frame for EASI90 is Weeks 2, 4, 8, 12, 20, 24, and 36.

  14. Difference in the percent CFB in EASI total score

    Time frame: Weeks 2, 4, 8, 12, 20, 24 and 36

  15. Difference in the percent CFB in Body Surface Area (BSA)

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24 and 36

  16. Difference in the proportion of patient Oriented Eczema Measure (POEM) response based on a participant achieving ≥4-point improvement from baseline in POEM

    Time frame: Weeks 4, 8, 16, 24 and 36

  17. Difference in the proportion of DLQI response based on a participant achieving ≥4-point improvement from baseline in DLQI at scheduled time points except that included as a key secondary endpoint for participants 16 years or older

    Time frame: Weeks 4, 8, 24 and 36

  18. Difference in the proportion of patient global impression of disease severity (PGI-S) response based on a participant achieving a score of None or Mild (0 or 1) in PGI-S

    Time frame: Weeks 4, 8, 16, 24 and 36

  19. Difference in the proportion of patient global impression of change in clinical status (PGI-C) response based on a participant achieving "Much Better" in PGI-C

    Time frame: Weeks 4, 8, 16, 24 and 36

  20. Difference in the proportion of responders for Atopic Dermatitis Control Tool (ADCT) response based on a participant achieving ≥5-point improvement from baseline in ADCT

    Time frame: Weeks 4, 8, 16, 24 and 36

  21. Difference in the mean CFB in POEM

    Time frame: Weeks 4, 8, 16, 24 and 36

  22. Difference in the mean CFB in DLQI at scheduled time points for participants 16 years or older

    Time frame: Weeks 4, 8, 16, 24 and 36

  23. Difference in the mean CFB in Children's Dermatology Life Quality Index (CDLQI) at scheduled time points for participants 12 to <16 years of age

    Time frame: Weeks 4, 8, 16, 24 and 36

  24. Difference in the mean CFB in weekly averages of PP-NRS

    Time frame: Week 1 through Week 24, plus Week 36

07

Study locations

19 of 23 sites recruiting
  • Cahaba Dermatology & Skin Health Center
    Birmingham, Alabama 35244, United States
    Recruiting
  • ORSO Health
    Scottsdale, Arizona 85254, United States
    Recruiting
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
    Recruiting
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
    Not yet recruiting
  • Northridge Clinical Trials
    Northridge, California 91325, United States
    Recruiting
  • University Clinical Trials, Inc
    San Diego, California 92123, United States
    Recruiting
  • Focus Clinical Research
    West Hills, California 91307, United States
    Not yet recruiting
  • Pediatric Skin Research
    Miami, Florida 33156, United States
    Recruiting
  • AllerVie Clinical Research
    Panama City, Florida 32405, United States
    Recruiting
  • GCP Research , Global Clinical Professionals
    St. Petersburg, Florida 33714, United States
    Recruiting
  • Marietta Dermatology Clinical Research, Inc.
    Marietta, Georgia 30060, United States
    Recruiting
  • Aeroallergy Research Laboratories of Savannah, Inc
    Savannah, Georgia 31406, United States
    Recruiting
  • Red River Research Partners LLC
    Fargo, North Dakota 58103, United States
    Recruiting
  • Derm Texas
    Dallas, Texas 75235, United States
    Recruiting
  • Stryde Research-Epiphany Dermatology
    Southlake, Texas 76092, United States
    Recruiting
  • Innovaderm Research Inc
    Montreal, Quebec H2X 2V1, Canada
    Recruiting
  • Charme Clinique
    Matsudo, Chiba 270-2223, Japan
    Recruiting
  • Miyata Dermatology Clinic
    Matsudo, Chiba 271-0092, Japan
    Recruiting
  • Shibaki Dermatology Clinic
    Teine-ku, Hokkaido 006-0022, Japan
    Not yet recruiting
  • Aile Home Clinic Nagaoka
    Nagaoka, Niigata 940-0065, Japan
    Recruiting
  • Osaka Metropolitan University Hospital
    Osaka, Osaka 545-8586, Japan
    Not yet recruiting
  • Dermatology and Ophthalmology Kume Clinic
    Sakai, Osaka 593-8324, Japan
    Recruiting
  • NTT Medical Center Tokyo
    Shinagawa, Tokyo 141-8625, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 18 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 14, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Mar 10, 2028
CompletionEst.
Jun 2, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 1 site removed — first sites in Japan and Canada. 12 sites changed recruiting status (12 now recruiting)
Show 12 sites
  • Northridge Clinical Trials · Northridge, United StatesNot yet recruiting→Recruiting
  • AllerVie Clinical Research · Panama City, United StatesNot yet recruiting→Recruiting
  • Cahaba Dermatology & Skin Health Center · Birmingham, United StatesNot yet recruiting→Recruiting
  • ORSO Health · Scottsdale, United StatesNot yet recruiting→Recruiting
  • Kern Research, Inc. · Bakersfield, United StatesNot yet recruiting→Recruiting
  • Aeroallergy Research Laboratories of Savannah, Inc · Savannah, United StatesNot yet recruiting→Recruiting
  • Stryde Research-Epiphany Dermatology · Southlake, United StatesNot yet recruiting→Recruiting
  • Charme Clinique · Matsudo, JapanNot yet recruiting→Recruiting
  • Miyata Dermatology Clinic · Matsudo, JapanNot yet recruiting→Recruiting
  • Aile Home Clinic Nagaoka · Nagaoka, JapanNot yet recruiting→Recruiting
  • Dermatology and Ophthalmology Kume Clinic · Sakai, JapanNot yet recruiting→Recruiting
  • NTT Medical Center Tokyo · Shinagawa, JapanNot yet recruiting→Recruiting
Show 21 added (12 United States, 8 Japan, 1 Canada)
  • Cahaba Dermatology & Skin Health Center · Birmingham, United States
  • ORSO Health · Scottsdale, United States
  • Kern Research, Inc. · Bakersfield, United States
  • University Clinical Trials, Inc · San Diego, United States
  • Focus Clinical Research · West Hills, United States
  • Pediatric Skin Research · Miami, United States
  • Marietta Dermatology Clinical Research, Inc. · Marietta, United States
  • Aeroallergy Research Laboratories of Savannah, Inc · Savannah, United States
  • Red River Research Partners LLC · Fargo, United States
  • Derm Texas · Dallas, United States
  • Stryde Research-Epiphany Dermatology · Southlake, United States
  • Charme Clinique · Matsudo, Japan
  • Miyata Dermatology Clinic · Matsudo, Japan
  • Shibaki Dermatology Clinic · Teine-ku, Japan
  • Aile Home Clinic Nagaoka · Nagaoka, Japan
  • Dermatology and Ophthalmology Kume Clinic · Sakai, Japan
  • NTT Medical Center Tokyo · Shinagawa, Japan
  • Osaka Metropolitan University Hospital · Osaka, Japan
  • First OC Dermatology Research Inc · Fountain Valley, United States
  • Innovaderm Research Inc · Montreal, Canada
  • Osaka Metropolitan University Hospital · Osaka, Japan
Show 1 removed
  • Osaka Metropolitan University Hospital · Osaka, Japan
across 2 updates, Oct 15, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    3 sites added, 1 site removed — first site in Canada. 10 sites changed recruiting status (10 now recruiting)
    Show 10 sites
    • Cahaba Dermatology & Skin Health Center · Birmingham, United StatesNot yet recruiting→Recruiting
    • ORSO Health · Scottsdale, United StatesNot yet recruiting→Recruiting
    • Kern Research, Inc. · Bakersfield, United StatesNot yet recruiting→Recruiting
    • Aeroallergy Research Laboratories of Savannah, Inc · Savannah, United StatesNot yet recruiting→Recruiting
    • Stryde Research-Epiphany Dermatology · Southlake, United StatesNot yet recruiting→Recruiting
    • Charme Clinique · Matsudo, JapanNot yet recruiting→Recruiting
    • Miyata Dermatology Clinic · Matsudo, JapanNot yet recruiting→Recruiting
    • Aile Home Clinic Nagaoka · Nagaoka, JapanNot yet recruiting→Recruiting
    • Dermatology and Ophthalmology Kume Clinic · Sakai, JapanNot yet recruiting→Recruiting
    • NTT Medical Center Tokyo · Shinagawa, JapanNot yet recruiting→Recruiting
    Show 3 added (1 United States, 1 Canada, 1 Japan)
    • First OC Dermatology Research Inc · Fountain Valley, United States
    • Innovaderm Research Inc · Montreal, Canada
    • Osaka Metropolitan University Hospital · Osaka, Japan
    Show 1 removed
    • Osaka Metropolitan University Hospital · Osaka, Japan
    + 1 other change: verification date
  2. Oct 15, 2026
    18 sites added — first site in Japan. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Northridge Clinical Trials · Northridge, United StatesNot yet recruiting→Recruiting
    • AllerVie Clinical Research · Panama City, United StatesNot yet recruiting→Recruiting
    Show 18 added (11 United States, 7 Japan)
    • Cahaba Dermatology & Skin Health Center · Birmingham, United States
    • ORSO Health · Scottsdale, United States
    • Kern Research, Inc. · Bakersfield, United States
    • University Clinical Trials, Inc · San Diego, United States
    • Focus Clinical Research · West Hills, United States
    • Pediatric Skin Research · Miami, United States
    • Marietta Dermatology Clinical Research, Inc. · Marietta, United States
    • Aeroallergy Research Laboratories of Savannah, Inc · Savannah, United States
    • Red River Research Partners LLC · Fargo, United States
    • Derm Texas · Dallas, United States
    • Stryde Research-Epiphany Dermatology · Southlake, United States
    • Charme Clinique · Matsudo, Japan
    • Miyata Dermatology Clinic · Matsudo, Japan
    • Shibaki Dermatology Clinic · Teine-ku, Japan
    • Aile Home Clinic Nagaoka · Nagaoka, Japan
    • Dermatology and Ophthalmology Kume Clinic · Sakai, Japan
    • NTT Medical Center Tokyo · Shinagawa, Japan
    • Osaka Metropolitan University Hospital · Osaka, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07765888
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Aug 17, 2026
Primary completion
Mar 10, 2028 (estimated)
Completion
Jun 2, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Start the discussion